Previous 10 | Next 10 |
Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting PR Newswire CAMBRIDGE, Mass. , May 26, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (...
Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides NNVC +11%. Travere Therapeutics TVTX +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix CMRX -58%. Eliem Therapeutics ELYM -29%. Humacyte (HUMA) -20%. Va...
Leap Therapeutics press release (NASDAQ:LPTX): Q1 GAAP EPS of -$0.09 beats by $0.01. Cash and cash equivalents totaled $103.2 million at March 31, 2022. Shares +2.73% PM. For further details see: Leap Therapeutics GAAP EPS of -$0.09 beats by $0.01
Leap Therapeutics Reports First Quarter 2022 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, toda...
3 Penny Stocks for Your Late-April 2022 Watchlist What are the best penny stocks to buy in 2022? This is a question that many investors are asking as we continue to barrel through an extremely volatile period in the stock market. And while there are many factors to consider when trying ...
Leap Therapeutics press release (NASDAQ:LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01. Revenue of $0.38M (flat Y/Y) beats by $0.08M. CEO comment: "Following our public offering, we are well funded to advance DKN-01 into the next stages of development in G/GEJ and other cancers, and we look forw...
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire CAMBRIDGE, Mass. , March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference PR Newswire CAMBRIDGE, Mass. , March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-onc...
I bought LPTX stock expecting a quick profit after a spike following data. The spike did happen, but I bought a little too high. I am expecting part B data to be strong enough for me to make a profit and exit. For further details see: Leap Therapeutics: Waiting For One M...
Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients Companion diagnostic supports patient identification and enrollment into clinical trials of Leap Therapeutics' DKK1 inhibitor, DKN-01 PR Newswire CAMBRIDGE, M...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...